Research · Single-study breakdown
The Single Amino Acid That May Explain Why GLP-1 Drugs Keep Working
What this means for you
If you are on a GLP-1 drug, this finding does not change anything about your treatment today. Nothing here tells you whether to start, stop, switch, or change the dose of any medication you are on. Nothing here proves the same switch exists, or works the same way, in a living person’s pancreas.
What it does offer is a glimpse of why the drugs may hold up over months rather than burning out — a question doctors have noticed but could not fully answer. The researchers themselves wrote that their next step has to be testing this in real human islet tissue before anyone knows whether it applies to human metabolism or diabetes. Until that happens, this is a piece of the puzzle, not a new option at the pharmacy.
The short-term story everyone already knows
When a GLP-1 drug reaches a beta cell, it locks onto a receptor on the cell’s surface. That triggers a chain reaction inside the cell: a signal called cAMP rises, an enzyme called PKA turns on, and PKA flips a switch on a protein called CREB. CREB then turns on a set of genes that make the cell release insulin. This happens fast, within minutes, and scientists have understood it for years.
The question nobody had answered
That quick reaction explains why a GLP-1 drug helps right after you take it. It does not explain why beta cells seem to hold up better over months of treatment. Something else has to be happening that changes how the cell behaves long-term, not just in the moment.
What the Salk team found
The researchers, led by Sam Van de Velde and Marc Montminy, looked for proteins that help GLP-1 drugs change which genes a beta cell keeps switched on over time. They found one called Med14. Med14 is a structural piece of a much larger machine called Mediator, made of 30 different proteins working together. Mediator is not specific to insulin or the pancreas. Nearly every gene in the body needs it to turn on.
Med14 is a general-purpose part. What the researchers found is that in beta cells treated for a long stretch with a GLP-1 drug (they used a lab version called Exendin-4, not a specific brand-name product), Med14 picks up a small chemical tag at one exact spot: a building block called serine, at position 983 in the protein. Adding that tag is called phosphorylation. Think of it as attaching a small chemical flag that changes how the protein behaves, without changing what protein it is.
Why one flag on one spot matters
To test whether that one flag mattered, the researchers changed that exact spot in mice so the flag could never attach. Alanine, a different building block, is not able to carry the tag. In those mice, the beta cells lost most of the long-term gene response to Exendin-4. The drug still reached the cell, but the sustained switch-flipping did not happen the same way.
More strikingly, the pancreas tissue in those altered mice ended up with more alpha cells relative to beta cells than in normal mice. Alpha and beta cells are neighbors inside a structure called an islet; beta cells make insulin, and alpha cells make a different hormone, glucagon, which raises blood sugar. The researchers noted that this shifted balance looked similar to what is seen in the pancreas of mice with type 2 diabetes. The beta cells in the altered mice were also missing markers of a beta-cell subtype that normally expands when mice eat a high-fat diet, which hints this same switch may help beta cells adjust to how much fat or sugar they are handling.
Why a general-purpose part is the interesting piece
Mediator, the machine Med14 belongs to, runs almost every gene in the body. It is not built to do anything specific to insulin or the pancreas on its own. The puzzle the researchers were chasing is how a hormone can use a generic, shared piece of cell machinery to produce an effect in one specific cell type and not everywhere else. This paper is one answer: a single chemical flag, on one exact spot of a shared protein, seems to be enough to steer that generic machine toward a beta-cell-specific job. The researchers also found that the same spot responds to cholesterol as well as to the drug, which suggests this one flag might be a place where a hormone signal and a nutrition signal both land.
What this study can't tell us
- Animals and cells, not people — the study was done in rat cell lines and mouse pancreas tissue. Nothing here proves the same switch exists, or works the same way, in a living person’s pancreas.
- No approved medication was tested — the study used a lab tool compound called Exendin-4, not any brand-name GLP-1 drug.
- Not a treatment pathway yet — this is not a new drug, and Med14 is not a drug target that is close to becoming a treatment.
- The researchers’ own next step — they wrote that this has to be tested in real human islet tissue before anyone knows whether it applies to human metabolism or diabetes.
Why this is still worth reading
Health reporting on GLP-1 drugs often says these medicines “protect” the pancreas or “work differently over time,” without ever showing what backs that claim up. This paper is a genuine, carefully controlled piece of that puzzle, done by a serious research group and published in a way anyone can read for free. The honest version — a single chemical flag on one spot of a shared cell machine that may help decide which genes a beta cell keeps running — is a more interesting story than a vague claim about protection. It is also, as of today, a finding in mice and rat cells, not yet a finding about people. That gap is the whole reason more research is needed before this changes anything about how anyone is treated.
Sources
- Med14 phosphorylation shapes genomic response to GLP-1 agonists — Proceedings of the National Academy of Sciences (2026) · doi:10.1073/pnas.2536772123
- Med14 phosphorylation — supporting information — Proceedings of the National Academy of Sciences (2026) · doi:10.1073/pnas.2536772123
Not medical advice. Educational summary of published research. Last reviewed Sep 28, 2026.